日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Using antagonistic pleiotropy to design a chemotherapy-induced evolutionary trap to target drug resistance in cancer

利用拮抗性多效性设计化疗诱导的进化陷阱,以靶向癌症耐药性。

Kevin H Lin # ,Justine C Rutter # ,Abigail Xie ,Bryann Pardieu ,Emily T Winn ,Reinaldo Dal Bello ,Antoine Forget ,Raphael Itzykson ,Yeong-Ran Ahn ,Ziwei Dai ,Raiyan T Sobhan ,Gray R Anderson ,Katherine R Singleton ,Amy E Decker ,Peter S Winter ,Jason W Locasale ,Lorin Crawford ,Alexandre Puissant ,Kris C Wood

Systematic Dissection of the Metabolic-Apoptotic Interface in AML Reveals Heme Biosynthesis to Be a Regulator of Drug Sensitivity

对 AML 中代谢-凋亡界面的系统解剖表明血红素生物合成是药物敏感性的调节剂

Kevin H Lin, Abigail Xie, Justine C Rutter, Yeong-Ran Ahn, Julia M Lloyd-Cowden, Amanda G Nichols, Ryan S Soderquist, Timothy R Koves, Deborah M Muoio, Nancie J MacIver, Jatinder K Lamba, Timothy S Pardee, Chad M McCall, David A Rizzieri, Kris C Wood

Dysregulation of mitochondrial dynamics proteins are a targetable feature of human tumors

线粒体动力学蛋白失调是人类肿瘤的一个可靶向特征

Gray R Anderson, Suzanne E Wardell, Merve Cakir, Catherine Yip, Yeong-Ran Ahn, Moiez Ali, Alexander P Yllanes, Christina A Chao, Donald P McDonnell, Kris C Wood

Prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor, increases in vitro toxicity of PARP inhibition by preventing Rad51 foci formation in BRCA wild type high-grade serous ovarian cancer

Prexasertib 是一种细胞周期检查点激酶 1 和 2 抑制剂,它通过阻止 BRCA 野生型高级别浆液性卵巢癌中的 Rad51 病灶形成来增加 PARP 抑制的体外毒性

Ethan Brill, Takuhei Yokoyama, Jayakumar Nair, Minshu Yu, Yeong-Ran Ahn, Jung-Min Lee